Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition comprising same

The present invention relates to an antibody targeting VEGFR-2, and more particularly a dual-target antibody of novel form in which calcium-binding EGF-like domains 11 and 12 of human Notch1 are bound to the N-terminal of the Tanibirumab light chain, a gene coding for same, a recombinant expression vector comprising the gene, host cells that have been genetically modified by using the recombinant expression vector and a method of producing a dual-target antibody by culturing the host cells, a pharmaceutical composition comprising the dual-target antibody, and a method for measuring the DLL4 antagonist efficacy of the dual-target antibody wherein Notch 1 activity is measured by the co-culturing of human umbilical endothelial cells (HUVEC) and a cell strain expressing human DLL4(hDLL4). The dual-target antibody according to the present invention has the advantages that, by more effectively simultaneously disrupting signal transmission following two different pathways of VEGF/VEGFR-2 and DLL4/Notch1, it is possible to treat various diseases associated with vasculogenesis such as tumours and, more particularly, possible to overcome the resistance that occurs following the use of a neovascular therapeutic agent alone, and that, by directly targeting cancer stem cells, it is possible to fundamentally prevent the recurrence of cancer.